It’s not every day that a groundbreaking scientific discovery leads to a potential new class of medicines. But that’s exactly what’s happening at Alnylam. From the "Eureka!" moment of discovering RNA interference (RNAi) to the clinical progress and the potential patient impact of the development of RNAi therapeutics, this 15-year journey involved the passion and persistence of countless people—people who accepted the challenge and fought for the potential of RNAi every step of the way.